Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal anti…
Biotechnology
US, New York [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Y-mAbs Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | -2.2400 | -2.989 | 0 | 15 | -78 | -99 | -82 | -99 | -83 | -100 | 19 | 19 |
| 2021 | -2.9500 | -1.077 | 20 | 35 | -118 | -24 | -119 | -21 | -119 | -131 | 44 | 44 |
| 2022 | -1.3000 | -2.695 | 34 | 54 | -56 | -122 | -54 | -119 | -115 | -120 | 54 | 67 |
| 2023 | -2.2000 | -0.666 | 65 | 82 | -96 | -21 | -94 | -131 | -94 | -132 | 60 | 65 |
| 2024 | -0.4900 | -0.629 | 84 | 88 | -21 | -23 | -25 | -40 | -25 | -40 | 44 | 109 |
| 2025 | - | -0.589 | - | 104 | - | -29 | - | -47 | - | -48 | - | 129 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |